Drugs / hAd5-S-Fusion+N-ETSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04591717 | Oct 2020 → Apr 2022 | COVID-19 | ImmunityBio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAd5-S-Fusion+N-ETSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04591717 ↗ |
| Modality | Vaccine | “hAd5-S-Fusion+N-ETSD vaccine” NCT04591717 ↗ |
| Route | Subcutaneous | “0.5 mL of hAd5-S-Fusion+N-ETSD SC” NCT04591717 ↗ |